Novo Nordisk ($NVO) in August bought a plant in New Hampshire that Japan's Olympus Biologics was giving up. Now it is looking for people to help operate it.
The Danish drugmaker said Wednesday that it would hire up to 90 people to work at the facility in West Lebanon, where it will make products for the treatment of hemophilia, including the long-acting recombinant factor VIII, N8-GP for those with hemophilia A.
"We're pleased to be bringing this site back to life, and make it a part of Novo Nordisk's growing network of manufacturing sites," Steen Weber Jensen, a Novo Nordisk VP, said in a statement Wednesday.
At the time it bought the facility, Novo said it would keep on some of the 130 Olympus employees to get the plant ready for production of active pharmaceutical ingredients.
Olympus was manufacturing mammalian cells at the facility, but was never able to get its business established in the U.S. In addition to closing the plant, Olympus closed its headquarters in Hopkinton, MA, where about 80 people worked. Shortly before putting the plant on the block, Olympus had added clinical aseptic fill capacity, with barrier isolator technology, to the 180,000 square foot facility.
The New Hampshire plant becomes Novo's second manufacturing facility in the U.S. It has an insulin-production plant in Clayton, NC.
- here's the release